A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
A present there is no safe treatment for reducing rate at which disability worsens in people
with secondary progressive multiple sclerosis. Recent research has suggested the possibility
that drugs that act by blocking the entry of sodium into nerve cells can protect nerve fibres
in the brain and spinal cord. In this trial, the investigators will test whether one such
drug, called lamotrigine, can prevent damage to nerve fibres and reduce the rate at which MS
worsens. The period of treatment in the trial will run for 2 years.